
Pro-Dex, Inc. (NASDAQ:PDEX – Free Report) – Research analysts at Ascendiant Capital Markets upped their Q2 2027 EPS estimates for shares of Pro-Dex in a research note issued to investors on Sunday, November 15th. Ascendiant Capital Markets analyst E. Woo now anticipates that the medical instruments supplier will earn $0.73 per share for the quarter, up from their previous estimate of $0.72. Ascendiant Capital Markets has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Pro-Dex’s current full-year earnings is $3.32 per share. Ascendiant Capital Markets also issued estimates for Pro-Dex’s FY2027 earnings at $3.32 EPS, Q1 2028 earnings at $0.78 EPS, Q2 2028 earnings at $0.82 EPS, Q3 2028 earnings at $0.90 EPS, Q4 2028 earnings at $0.96 EPS and FY2028 earnings at $3.47 EPS.
Other equities analysts have also recently issued reports about the company. Weiss Ratings upgraded Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, November 10th. Zacks Research lowered shares of Pro-Dex from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $80.00.
Pro-Dex Stock Performance
Shares of Pro-Dex stock opened at $63.00 on Friday. Pro-Dex has a one year low of $30.55 and a one year high of $77.00. The firm has a market capitalization of $201.60 million, a price-to-earnings ratio of 17.26 and a beta of 0.12. The business has a 50-day simple moving average of $64.91 and a 200 day simple moving average of $58.27. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.19 and a quick ratio of 2.49.
Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $20.56 million for the quarter, compared to analysts’ expectations of $20.40 million. Pro-Dex had a net margin of 15.12% and a return on equity of 26.18%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PDEX. Goldman Sachs Group Inc. lifted its holdings in Pro-Dex by 6.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 19,945 shares of the medical instruments supplier’s stock worth $1,376,000 after buying an additional 1,234 shares during the period. Apriem Advisors bought a new stake in shares of Pro-Dex in the 3rd quarter worth approximately $1,385,000. First Trust Advisors LP increased its stake in shares of Pro-Dex by 26.2% during the third quarter. First Trust Advisors LP now owns 7,487 shares of the medical instruments supplier’s stock valued at $517,000 after buying an additional 1,553 shares during the period. Global Retirement Partners LLC increased its stake in shares of Pro-Dex by 7,790.1% during the third quarter. Global Retirement Partners LLC now owns 78,901 shares of the medical instruments supplier’s stock valued at $5,444,000 after buying an additional 77,901 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Pro-Dex by 1,443.6% during the third quarter. Russell Investments Group Ltd. now owns 11,191 shares of the medical instruments supplier’s stock valued at $772,000 after buying an additional 10,466 shares during the period. 15.28% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Pro-Dex news, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $59.36, for a total transaction of $45,410.40. Following the sale, the chief executive officer owned 79,228 shares in the company, valued at $4,702,974.08. This represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the completion of the transaction, the chief financial officer owned 21,870 shares of the company’s stock, valued at $1,340,631. This trade represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 22,300 shares of company stock valued at $1,351,657 over the last three months. Company insiders own 48.00% of the company’s stock.
Trending Headlines about Pro-Dex
Investors following PDEX have been watching these headlines:
- Positive Sentiment: Ascendiant Capital Markets raised its FY2027 EPS estimate to $3.32 from $3.09 and FY2028 to $3.47 from $3.36, while increasing several 2028 quarterly forecasts. It kept its Buy rating and $80 price target, signaling a favorable longer-term outlook. Analyst estimates
- Neutral Sentiment: Shareholders elected the board and approved key proposals. The available report does not specify the proposals, so the investment implications are unclear. Shareholder meeting report
- Negative Sentiment: Ascendiant trimmed its Q3 and Q4 2027 EPS estimates by one cent each, to $0.81 and $0.86, respectively. The reductions are small but temper the positive longer-term revisions. Analyst estimates
Pro-Dex Company Profile
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.
See Also
- Five stocks we like better than Pro-Dex
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
